OBJECTIVE: Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) is a nuclear receptor found in platelets. PPARbeta/delta agonists acutely inhibit platelet function within a few minutes of addition. As platelets are anucleated, the effects of PPARbeta/delta agonists on platelets must be nongenomic. Currently, the particular role of PPARbeta/delta receptors and their intracellular signaling pathways in platelets are not known. METHODS AND RESULTS: We have used mice lacking PPARbeta/delta (PPARbeta/delta(-/-)) to show the effects of the PPARbeta/delta agonist GW501516 on platelet adhesion and cAMP levels are mediated specifically by PPARbeta/delta, however GW501516 had no PPARbeta/delta-specific effect on platelet aggregation. Studies in human platelets showed that PKCalpha, which can mediate platelet activation, was bound and repressed by PPARbeta/delta after platelets were treated with GW501516. CONCLUSIONS: These data provide evidence of a novel mechanism by which PPAR receptors influence platelet activity and thereby thrombotic risk.
OBJECTIVE:Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) is a nuclear receptor found in platelets. PPARbeta/delta agonists acutely inhibit platelet function within a few minutes of addition. As platelets are anucleated, the effects of PPARbeta/delta agonists on platelets must be nongenomic. Currently, the particular role of PPARbeta/delta receptors and their intracellular signaling pathways in platelets are not known. METHODS AND RESULTS: We have used mice lacking PPARbeta/delta (PPARbeta/delta(-/-)) to show the effects of the PPARbeta/delta agonist GW501516 on platelet adhesion and cAMP levels are mediated specifically by PPARbeta/delta, however GW501516 had no PPARbeta/delta-specific effect on platelet aggregation. Studies in human platelets showed that PKCalpha, which can mediate platelet activation, was bound and repressed by PPARbeta/delta after platelets were treated with GW501516. CONCLUSIONS: These data provide evidence of a novel mechanism by which PPAR receptors influence platelet activity and thereby thrombotic risk.
Authors: Louise S Harrington; Laura Moreno; Anna Reed; Stephen J Wort; Béatrice Desvergne; Christopher Garland; Lan Zhao; Jane A Mitchell Journal: PLoS One Date: 2010-03-04 Impact factor: 3.752
Authors: Baktybek Kojonazarov; Himal Luitel; Akylbek Sydykov; Bhola K Dahal; Mark J Paul-Clark; Sara Bonvini; Anna Reed; Ralph T Schermuly; Jane A Mitchell Journal: Pulm Circ Date: 2013-12 Impact factor: 3.017
Authors: Katie L Lannan; Julie Sahler; Nina Kim; Sherry L Spinelli; Sanjay B Maggirwar; Olivier Garraud; Fabrice Cognasse; Neil Blumberg; Richard P Phipps Journal: Front Immunol Date: 2015-02-13 Impact factor: 7.561